Variant Bio is developing therapeutics by analyzing the genetic data of individuals with exceptional health traits, utilizing insights from human genomics to identify disease mechanisms. This approach aims to enhance the success rates of clinical trials, addressing the high costs and failure rates associated with traditional drug development.
Funding
$131.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SVFounders
Product
Problem
Traditional drug development faces challenges due to high costs and failure rates, often stemming from a limited understanding of the underlying genetic factors influencing disease mechanisms. This lack of insight can lead to ineffective clinical trials and prolonged timelines for bringing new therapies to market.
Solution
Variant Bio leverages human genomics to identify the genetic basis of exceptional health traits and disease resistance in specific populations. By studying individuals with unique health characteristics, the company aims to uncover novel drug targets and biomarkers that can improve the success rate of clinical trials. Their approach focuses on translating genetic discoveries into targeted therapeutics, addressing unmet medical needs with a data-driven strategy. Variant Bio's research seeks to enhance the efficiency and effectiveness of drug development by identifying and validating promising therapeutic targets through human genetic insights.
Target Audience
The primary target audience includes pharmaceutical companies, research institutions, and patients seeking innovative therapies for diseases with a strong genetic component.
Features
- Genomic analysis of individuals with exceptional health-related traits to identify protective genetic variants.
- Target discovery and validation based on human genetic data.
- Development of therapeutics that mimic or modulate the effects of protective genes.
- Focus on identifying disease mechanisms through human genomics.
- Ethical and culturally sensitive approach to genomic research, including benefit-sharing programs with partner communities.